Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care?

Abstract

O ne of the major milestones in medicine during the last 40 years has been strong evidence from well-designed clinical trials showing that blood pressure-lowering interventions reduce hypertension-related morbidity and mortality. 1 Whereas initially these results were in most cases achieved with high-dose thiazide diuretics, subsequent research demonstrated that dose reduction, including combination with potassium-sparing agents, is effective and decreases the risk of adverse effects. 2,3 Since then, several new antihypertensive agents have been developed, but meta-analyses have not indicated a superior beneficial effect of these agents over conventional ones. 4,5 However, many hypertension experts do not recommend thiazide diuretics as first-line treatment for hypertension, and guidelines are inconsistent. 6 -8 There were 2 major reasons for this failure to transform sound scientific evidence into practice. Firstly, potential thiazideinduced metabolic effects (eg, a transient increase in serum cholesterol and a serum potassium-dependent slight increase in blood glucose levels) were thought to be responsible for the so-called shortfall in the reduction in cardiovascular events (the gap between the epidemiologically estimated decrease in the risk of hypertension-related events and the magnitude of the decrease actually achieved in intervention trials). 9 Second, protective effects beyond the blood pressurelowering effect were attributed to newer agents, which include ␣-blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), and, more recently, angiotensin receptor blockers. Despite the fact that this theory was not confirmed in head-to-head trials, the vigorous marketing of these agents, combined with a campaign against the use of diuretics, changed prescription habits worldwide. 10 This controversy was the reason for the largest hypertension study ever conducted: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). The results and implications of ALLHAT and 2 other controversially discussed studies, namely, the Second Australian National Blood Pressure Study (ANBP2) and the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), are discussed here. It should be noted that their comparability is limited by different study designs and by marked differences in baseline blood pressures and risk profiles. An overview of these studies is presented in Tables 1 and 2. The ALLHAT, ANBP2, and ASCOT-BPLA Hypertension TrialsALLHAT was sponsored by the US National Heart, Lung, and Blood Institute in conjunction with the Department of Veterans Affairs. The National Heart, Lung, and Blood Institute received financial support from Pfizer Inc, USA, and its responsibilities included the collection, interpretation, and analysis of data, and the decision to submit the article for publication. Study medications were supplied by Pfizer Inc and AstraZeneca, USA. 11,12 This randomized, double-blind, controlled trial included 42 418 h...

The Kallikrein‐Kinin System as a Regulator of Cardiovascular and Renal Function

“…The accumulated literature on (1) antibodies to kinins and kallikrein, (2) kinin antagonists and kininase inhibitors, (3) gene knockout (KO) models of the kallikrein-kinin system, and (4) kininogen-deficient rats as well as spontaneous genetic mutations in humans has allowed us to study the role of kinins in specific physiological and pathological conditions.…”

“…B 2 also forms a complex with endothelial nitric oxide synthase (eNOS), suppressing NO, and this effect is reversed by bradykinin (116). Moreover, B 2 has been found to interact directly with AT 2 (3), B 1 (15), ACE (236), and even other B 2 receptors (forming homodimers) (8). Since preeclampsia has been linked to an increase in AT 1 and B 2 heterodimers that could mediate the enhanced response to angiotensin II (6), it seems reasonable to posit that interaction between AT 1 and B 2 could play a pathophysiological role in some conditions.…”

Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?

“…18 Although the primary outcome of cardiovascular events or all-cause mortality was marginally lower in the ACE inhibitor group, this study has been challenged on methodologic grounds. 19 Thus, clinical trials have not unambiguously resolved the question of whether Ang II promotes LVH by a direct effect on the heart, and the topic has justifiably been the subject of a great deal of experimental research.…”

Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis

“…The present study focused on treatment with beta blockers; future studies should assess the relationship between persistence and medical costs in other classes of antihypertensives, including calcium channel blockers, angiotensin-II receptor blockers, angiotensin-converting enzyme inhibitors, and diuretics. This may be particularly interesting given the current controversy over the efficacy of certain beta blockers, such as atenolol, in reducing cardiovascular mortality and myocardial infarction 44,45 .…”